Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.
Thorac Cancer. 2022 May;13(10):1479-1489. doi: 10.1111/1759-7714.14417. Epub 2022 Apr 8.
Biomarker assessments for nivolumab monotherapy efficacy in previously treated patients with non-small cell lung cancer (NSCLC) remain unclear. We evaluated whether body mass index (BMI) and Glasgow prognostic score (GPS) are useful for assessing the efficacy of nivolumab alone as a second-line treatment in patients with pretreated NSCLC.
Data of 99 patients treated with second-line nivolumab monotherapy for NSCLC between January 2016 and December 2019 were evaluated for prognostic values of BMI and GPS to assess their usefulness in predicting progression-free survival (PFS) and overall survival (OS).
The Eastern Cooperative Oncology Group-performance status (PS) independently predicted the second-line nivolumab monotherapeutic effect; good PS (0-1) correlated with significantly longer PFS (4.3 vs. 1.9 months, log-rank; p = 0.0004) and OS (17.7 vs. 4.6 months, log-rank; p < 0.0001) than poor PS. BMI independently predicted survival, with high BMI (≥22.1 kg/m ) associated with significantly longer OS (19.1 vs. 8.5 months, log-rank; p = 0.0023) than low BMI (<22.1 kg/m ). However, GPS showed no significant difference for PFS or OS.
Among patients with NSCLC treated with nivolumab monotherapy as second-line treatment, PS was significantly correlated with both PFS and OS and BMI with OS. Thus, BMI could be a useful predictor of survival in these patients.
对于先前接受过治疗的非小细胞肺癌（NSCLC）患者，纳武利尤单抗单药治疗疗效的生物标志物评估仍不清楚。我们评估了体重指数（BMI）和格拉斯哥预后评分（GPS）是否可用于评估纳武利尤单抗作为二线治疗在预处理 NSCLC 患者中的疗效。
评估了 2016 年 1 月至 2019 年 12 月期间接受二线纳武利尤单抗单药治疗的 99 例 NSCLC 患者的 BMI 和 GPS 数据，以评估其对无进展生存期（PFS）和总生存期（OS）的预测价值。
东部肿瘤协作组表现状态（PS）独立预测了二线纳武利尤单抗单药治疗效果；PS 较好（0-1）与显著更长的 PFS（4.3 与 1.9 个月，对数秩；p=0.0004）和 OS（17.7 与 4.6 个月，对数秩；p<0.0001）相关，而 PS 较差。BMI 独立预测生存，高 BMI（≥22.1 kg/m）与显著更长的 OS（19.1 与 8.5 个月，对数秩；p=0.0023）相关，而低 BMI（<22.1 kg/m）则没有。然而，GPS 对 PFS 或 OS 没有显著差异。
在接受纳武利尤单抗单药二线治疗的 NSCLC 患者中，PS 与 PFS 和 OS 显著相关，BMI 与 OS 相关。因此，BMI 可能是这些患者生存的有用预测指标。
